The FDA granted fast track designation in July for multiple oncology programs spanning colorectal cancer, anal cancer, and malignant pleural mesothelioma, alongside priority review actions for additional hard-to-treat disease settings. The designations include SOT109, Oncolytics’ pelareorep plus atezolizumab, and other advanced-stage efforts targeting urgent unmet need. For colorectal cancer, SOTIO Biotech’s CDH17-targeting antibody-drug conjugate SOT109 entered fast track for advanced unresectable or metastatic disease after standard options. In anal cancer, Oncolytics’ pelareorep in combination with atezolizumab received fast track based on GOBLET study efficacy signals. In prostate cancer, Pfizer’s talazoparib supplemental NDA was accepted for priority review in combination with enzalutamide, supported by phase 3 TALAPRO-3 results. Taken together, the actions show continued regulatory emphasis on oncology combinations and targeted mechanisms where response and progression data support faster evaluation.